Agilent Technologies Introduces SureSelect Human All-Exon UTRs for Next-Generation Sequencing

Agilent Technologies Inc. introduced SureSelect Human All-Exon V5 and V5 + UTRs for next-generation sequencing. The new all-exon solutions incorporate the latest advances from Agilent Genomics, the originator of target enrichment for human exomes.

SureSelect Human All-Exon V5 continues to build on the market-leading SureSelect Target Enrichment platform, enabling faster turnaround—producing exome samples ready for sequencing the next day. It also provides even greater sequencing efficiencies as well as comprehensive coverage of the most current genomics databases, including RefSeq, CCDS, GENCODE, miRBase, TCGA and UCSC.

Optimized to provide maximum specificity and sensitivity, these new all-exon solutions require only 4 Gb of total sequencing, which represents up to 60 percent less sequencing compared with competitive human exome offerings.

 “We are excited to continue delivering high-performance exome target capture products,” said Kathleen Shelton, Agilent’s senior marketing director for genomics. “Our V5 and V5+ UTRs are the most up-to-date and comprehensive exome kits available. Together with a streamlined workflow, they enable greater sample throughput with significantly less sequencing—which means researchers can spend less time and expense on sequencing, and more time on discovery.”

The SureSelect Human All-Exon V5 is part of the SureSelect portfolio and available as a complete SureSelectXT or SureSelectXT2 solution. It is also well matched with SureSelect Custom and HaloPlex Target Enrichment Systems, which are ideal for follow-up studies.